Literature DB >> 8981687

On the relationship between response to treatment and survival time.

M Buyse1, P Piedbois.   

Abstract

In this paper we review several approaches which have been used to investigate the relationship between survival time and response to treatment. We show that the approaches based on summary data are subjected to various types of biases (publication bias, confounding by prognostic features, ecologic bias) and are therefore of doubtful value. We also discuss several approaches based on individual patient data. Comparisons of survival by response are generally subject to length-biased sampling, and are therefore inadequate. The landmark method is adequate when responses occur soon after starting treatment, but not when responses may appear later in the course of the disease. For responses which can occur over extended periods of time, response must be considered as a time-dependent covariate. Using data from randomized trials in advanced colorectal cancer, we show that response is a potent and independent prognostic factor for survival in this disease. Analyses using the landmark method yield results essentially equivalent to those in which response is considered as a time-dependent covariate. The hazard rate of responders is about half that of non-responders, after taking the patient's performance status into account. The issue of response as a surrogate marker for survival is taken up further in a separate paper.

Entities:  

Mesh:

Year:  1996        PMID: 8981687     DOI: 10.1002/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  24 in total

Review 1.  Modelling and simulation in the development and use of anti-cancer agents: an underused tool?

Authors:  Ferdinand Rombout; Leon Aarons; Mats Karlsson; Anthony Man; France Mentré; Peter Nygren; Amy Racine; Hans Schaefer; Jean-Louis Steimer; Iñaki Troconiz; Achiel van Peer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-12       Impact factor: 2.745

2.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

Authors:  Daniela Matei; Michael W Sill; Heather A Lankes; Koen DeGeest; Robert E Bristow; David Mutch; S Diane Yamada; David Cohn; Valerie Calvert; John Farley; Emanuel F Petricoin; Michael J Birrer
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

Review 3.  Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.

Authors:  Marc Buyse
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

4.  Landmark analysis: A primer.

Authors:  Charity J Morgan
Journal:  J Nucl Cardiol       Date:  2019-02-04       Impact factor: 5.952

5.  Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.

Authors:  Michael Haas; Rüdiger P Laubender; Petra Stieber; Stefan Holdenrieder; Christiane J Bruns; Ralf Wilkowski; Ulrich Mansmann; Volker Heinemann; Stefan Boeck
Journal:  Tumour Biol       Date:  2010-05-18

6.  Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.

Authors:  Mohammad Ehsanul Karim; Paul Gustafson; John Petkau; Helen Tremlett
Journal:  Am J Epidemiol       Date:  2016-07-25       Impact factor: 4.897

7.  Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.

Authors:  Leslie M Randall; Michael W Sill; Robert A Burger; Bradley J Monk; Barbara Buening; Joel I Sorosky
Journal:  Gynecol Oncol       Date:  2011-12-01       Impact factor: 5.482

Review 8.  Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.

Authors:  Rui Zhu; Dan Lu; Yu-Waye Chu; Akiko Chai; Michelle Green; Nancy Zhang; Jin Yan Jin
Journal:  AAPS J       Date:  2017-02-21       Impact factor: 4.009

9.  Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.

Authors:  Chikako Suzuki; Lennart Blomqvist; Thomas Hatschek; Lena Carlsson; Zakaria Einbeigi; Barbro Linderholm; Birgitta Lindh; Niklas Loman; Martin Malmberg; Samuel Rotstein; Martin Söderberg; Marie Sundqvist; Thomas M Walz; Gunnar Aström; Hirofumi Fujii; Hans Jacobsson; Bengt Glimelius
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

10.  Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.

Authors:  Jeremy M G Taylor; Anna S C Conlon; Michael R Elliott
Journal:  Clin Trials       Date:  2014-12-09       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.